NASDAQ · Biotechnology

Freeline Therapeutics Holdings plc (FRLN) Stock

$6.49 +0.15% NASDAQ: FRLN Healthcare

Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in its clinical development phase, focused on creating groundbreaking gene therapies. These innovative treatments leverage adeno-associated virus (AAV) vector technology to tackle inherited, systemic, and severely debilitating genetic conditions.

Valuation

MetricValue
Price$6.49
Market Cap$28.28M
P/E Ratio-0.29
P/B Ratio0.49
P/S Ratio0.00
EPS (TTM)$-22.52
52-Week High$8.74
52-Week Low$2.11
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-102.94%
ROA-102.69%
ROCE-176.82%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.11
Current Ratio2.18

Annual Financials (USD)

Metric20182019202020212022
Revenue$0$0$0$0$0
Operating Profit$-41.0M$-64.0M$-102.0M$-142.0M$-98.0M
Net Profit$-33.0M$-54.0M$-96.0M$-140.0M$-89.0M
EPS$-78.65$-127.39$-102.09$-58.98$-22.52
Op Margin—————

Balance Sheet (USD)

Metric20182019202020212022
Total Assets$32.0M$97.0M$269.0M$141.0M$87.0M
Total Liabilities$9.0M$12.0M$19.0M$21.0M$34.0M
Cash$16.0M$74.0M$230.0M$118.0M$47.0M
Borrowings$0$0$0$0$6.0M

Cash Flow (USD)

Metric20182019202020212022
Operating Cash Flow$-26.0M$-52.0M$-95.0M$-108.0M$-78.0M
Investing Cash Flow$-7.0M$-6.0M$-5.0M$-9.0M$-14.0M
Financing Cash Flow$38.0M$115.0M$243.0M$-1.0M$28.0M
Net Cash Flow$8.0M$58.0M$157.0M$-113.0M$-70.0M
Free Cash Flow$-30.0M$-55.0M$-97.0M$-112.0M$-85.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.13
FCF Yield-301.37%
Quick Ratio1.61
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALLKAllakos Inc. $0.33 +0.22% -0.25 $29.74M 0.00%
ANGNAngion Biomedica Corp. $1.00 +0.00% -0.42 $30.11M 0.00%
ANPCAnPac Bio-Medical Science Co., Ltd. $4.30 -3.15% -0.54 $26.97M 0.00%
ELEVElevation Oncology, Inc. $0.37 -2.12% -0.47 $21.63M 0.00%
LMNLLiminal BioSciences Inc. $8.50 +0.12% -0.03 $27.62M 0.00%

About Freeline Therapeutics Holdings plc

Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in its clinical development phase, focused on creating groundbreaking gene therapies. These innovative treatments leverage adeno-associated virus (AAV) vector technology to tackle inherited, systemic, and severely debilitating genetic conditions. The company's leading therapeutic candidate, verbrinacogene setparvovec (FLT180a), is presently undergoing Phase 1/2 clinical trials for the management of hemophilia B in adult males. Furthermore, Freeline's pipeline features FLT190, which is also in Phase 1/2 clinical evaluation for treating Fabry disease, and FLT201, a gene therapy designed to target the liver for type 1 Gaucher disease, likewise progressing through Phase 1/2 trials. Beyond these specific programs, the company is actively pursuing research initiatives across a range of other systemic gene therapy indications. Freeline was established in 2015 and operates from its headquarters in Stevenage, United Kingdom.

Freeline Therapeutics Holdings plc is headquartered in GB.

Freeline Therapeutics Holdings plc (FRLN) stock trades at $6.49 with a market capitalization of $28.28M. The stock is valued at a price-to-earnings (P/E) ratio of -0.29, price-to-book of 0.49, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.11 and $8.74, and currently trades 25.7% below its 52-week high.

On profitability, Freeline Therapeutics Holdings plc generates a return on equity (ROE) of -102.94%, return on capital employed of -176.82%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.freeline.life

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides